The Wall Street Journal reports that fake studies have led to thousands of retractions and millions of dollars in lost revenue for publishers of scientific journals. Wiley is closing 19 journals due to research fraud from “paper mills” that fabricate papers for a price. In another story, Amgen is accused of prioritizing profits over patients by marketing a high dose of a pricey cancer treatment instead of a lower, less toxic dose. The medication, Lumakras, received conditional approval three years ago and required further trials for full approval. The article is available exclusively to STAT+ subscribers.
Source link
We’re reading about fake studies, AbbVie investing in psychedelics
